Document Detail


Comprehensive long-term outcome of best drug treatment with or without add-on vagus nerve stimulation for epilepsy: a retrospective matched pairs case-control study.
MedLine Citation:
PMID:  23206433     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: In the treatment of epilepsy, the recommendation to add vagus nerve stimulation (VNS) to the best available drug therapy (BDT) mostly relies on uncontrolled studies which provide limited information about VNS-specific benefits. We report findings from a retrospective matched pairs case-control study comparing the long-term (>2 years) outcomes of BDT with or without VNS.
METHODS: Included were adult patients with therapy-refractory epilepsy who had undergone the pre-surgical work-up (baseline) and subsequently received BDT with VNS (BDT+VNS) or BDT alone (BDT group). Patients were matched in pairs for age, gender and follow-up. Health outcomes were assessed at least 24 months after the baseline by comprehensive postal surveys and included established psychometric scales.
RESULTS: We obtained data from 20 matched pairs of case and control patients. In both groups, seizures, health-related quality of life and mood improved over time. More BDT patients experienced a complete cessation of "major" seizures (12/20 vs. 4/20) whereas, in non-seizure free patients, BDT+VNS patients showed better seizure frequency reduction (>50% reduction: 12/19 vs. 7/16). BDT+VNS patients experienced equal drug related and additional VNS related side effects. No clinically relevant effect of VNS treatment was found on any psychological/psychosocial outcome measure.
CONCLUSION: This retrospective study provided no positive evidence for therapeutic benefits of adding VNS to BDT. The follow-up health status of BDT+VNS patients was slightly worse than in patients receiving BDT alone. Despite minor group differences at baseline the two patient groups who had failed presurgical evaluation were comparable. Therapeutic improvements during long-term BDT alone are often underestimated resulting in a misattribution of positive changes to VNS in uncontrolled studies and reviews. Currently, there is no incontrovertible evidence for the clinical effectiveness of adding VNS to BDT.
Authors:
Christian Hoppe; Lena Wagner; Judith M Hoffmann; Marec von Lehe; Christian E Elger
Related Documents :
24815913 - Hemispherotomy in rasmussen encephalitis: long-term outcome in an italian series of 16 ...
18173943 - Is there a role for combinations of antiplatelet agents in stroke prevention?
6784733 - Alpha-difluoromethylornithine (alpha dfmo) and phenoxybenzamine hydrochloride in the tr...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-12-01
Journal Detail:
Title:  Seizure     Volume:  22     ISSN:  1532-2688     ISO Abbreviation:  Seizure     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-06     Completed Date:  2013-10-24     Revised Date:  2014-10-21    
Medline Journal Info:
Nlm Unique ID:  9306979     Medline TA:  Seizure     Country:  England    
Other Details:
Languages:  eng     Pagination:  109-15     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anticonvulsants / therapeutic use*
Case-Control Studies
Combined Modality Therapy / trends
Epilepsy / diagnosis,  epidemiology*,  therapy*
Female
Follow-Up Studies
Humans
Male
Middle Aged
Retrospective Studies
Time Factors
Treatment Outcome
Vagus Nerve Stimulation / trends*
Chemical
Reg. No./Substance:
0/Anticonvulsants
Comments/Corrections
Comment In:
Seizure. 2013 Jun;22(5):409-10   [PMID:  23506645 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  CT pulmonary angiography in elderly patients: outcomes in patients aged >85 years.
Next Document:  Cleaning up the mess: cell corpse clearance in Caenorhabditis elegans.